Estamos no ar no ! Saiba mais
1,32 USD
+0,03
2,33%
No fechamento Atualizado 16 de out. 16:00 EDT
1 dia
2,33%
5 dias
-12,58%
1 mês
-12,58%
3 meses
-27,07%
6 meses
-7,69%
No acumulado do ano
-29,79%
1 ano
-22,81%
5 anos
-99,12%
10 anos
-99,77%
 

Sobre: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Funcionários: 118

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 16,7%
Neutro 66,7%
Negativo 16,7%
Neutro
GlobeNewsWire
há 18 dias
Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop
Collaboration pairs Cibus' platform for improving a plant's own genes with Crystal Crop's mustard varieties and its reach across India, with the goal of putting better-performing seed in growers' hands in a fraction of the time of conventional breeding Collaboration pairs Cibus' platform for improving a plant's own genes with Crystal Crop's mustard varieties and its reach across India, with the goal of putting better-performing seed in growers' hands in a fraction of the time of conventional breeding
Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop
Neutro
Seeking Alpha
há 2 meses
Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript
Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript
Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript
Negativo
Zacks Investment Research
há 2 meses
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.61 per share a year ago.
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
Positivo
MarketBeat
há 2 meses
Cibus Q2 Earnings Call Highlights
Cibus NASDAQ: CBUS reported second-quarter 2026 revenue of $1.0 million, compared with $0.9 million a year earlier, as the agricultural biotechnology company advanced its Sustainable Ingredients program and updated the expected timing of its initial rice launch in Latin America.
Cibus Q2 Earnings Call Highlights
Neutro
GlobeNewsWire
há 2 meses
Cibus Reports Second Quarter Financial Results and Provides Business Update
Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly net cash usage declined 19% sequentially and 31% year over year SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a technology company that uses biology to produce sustainable ingredients and helps farmers grow more food with fewer inputs, today announced its financial results for the quarter ended June 30, 2026, and provided a business update. Management will host a conference call and webcast today at 4:30 p.m.
Cibus Reports Second Quarter Financial Results and Provides Business Update
Neutro
GlobeNewsWire
há 2 meses
Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a technology company that helps farmers grow more food with fewer inputs, today announced that the company will report second quarter 2026 financial results on Thursday, August 13, 2026. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.
Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call
Neutro
GlobeNewsWire
há 4 meses
Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
Under new EU rules, crops improved without adding foreign DNA will be treated like conventionally bred crops, validating the approach Cibus has developed for 25 years Under new EU rules, crops improved without adding foreign DNA will be treated like conventionally bred crops, validating the approach Cibus has developed for 25 years
Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
Neutro
GlobeNewsWire
há 4 meses
Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced key leadership changes pursuant to the Company's previously announced succession planning strategy. As part of this plan, Craig Wichner, a board member since November 2025, has been appointed as the Company's Chief Executive Officer. Peter Beetham, who has served as the Company's Interim Chief Executive Officer, will continue his role as the Company's President and Chief Operating Officer. Concurrently, both Mr. Wichner and Dr. Beetham resigned from the Cibus Board of Directors as part of this reorganization and plan.
Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
Neutro
Seeking Alpha
há 5 meses
Cibus, Inc. (CBUS) Q1 2026 Earnings Call Transcript
Cibus, Inc. (CBUS) Q1 2026 Earnings Call Transcript
Cibus, Inc. (CBUS) Q1 2026 Earnings Call Transcript
Neutro
Zacks Investment Research
há 5 meses
Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.74 per share a year ago.
Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
Gráficos de preços implementados com Lightweight Charts™